Jay M. ("Marty") Tenenbaum is the founder and Chairman of CollabRx. Dr. Tenenbaum brings to CollabRx the unique perspective of a world-renowned Internet commerce pioneer and visionary. He was founder and CEO of Enterprise Integration Technologies, the first company to conduct a commercial Internet transaction (1992), secure Web transaction (1993) and Internet auction (1993). In 1994, he founded CommerceNet to accelerate business use of the Internet. In 1997, he co-founded Veo Systems, the company that pioneered the use of XML for automating business-to-business transactions. Dr. Tenenbaum joined Commerce One in January 1999, when it acquired Veo Systems. As Chief Scientist, he was instrumental in shaping the company's business and technology strategies for the Global Trading Web. Post Commerce One, Dr. Tenenbaum was an officer and director of Webify Solutions, which was sold to IBM in 2006, and Medstory, which was sold to Microsoft in 2007. Earlier in his career, Dr. Tenenbaum was a prominent AI researcher and led AI research groups at SRI International and Schlumberger Ltd. Dr. Tenenbaum is a fellow and former board member of the American Association for Artificial Intelligence, and a former consulting professor of Computer Science at Stanford. He currently serves as a director of Efficient Finance, Patients Like Me, and the Public Library of Science, and is a consulting professor of Information Technology at Carnegie Mellon's new West Coast campus. Dr. Tenenbaum holds B.S. and M.S. degrees in Electrical Engineering from MIT, and a Ph.D. from Stanford.

John Curd has been the President and Chief Medical Officer at Threshold Pharmaceuticals since 2007. He had joined Threshold Pharmaceuticals as a member of the management team to lead the clinical development of product development candidates including Threshold's hypoxia activated prodrug, TH-302. Prior to Threshold Pharmaceuticals, Dr. Curd was President and Chief Medical Officer at Novacea, Inc. since 2001. He had served in senior roles at Maxygen and VaxGen, Inc. from June 1999 to December 2001, and Vice President of Clinical Development at Genentech, Inc. from December 1991 to June 1999. While at Genentech, he directed the clinical development of Herceptin®, Rituxan®, Xolair®, and Raptiva®. From 1978 to 1991, Dr. Curd served in various positions including President of the Medical Staff at Scripps Clinical and Research Foundation in La Jolla, California. Dr. Curd holds a B.S. in chemistry from Princeton University and an M.D. from Harvard Medical School.

Jeff Shrager is the CTO of CollabRx, and a consulting associate professor in the Symbolic Systems program at Stanford University. As a computational psychologist of science, Dr. Shrager seeks to understand how science works, and to build human-computer networks that facilitate discovery. Previously, Dr. Shrager co-founded several scientific-computing start-ups (including Afferent Systems, acquired by MDL), and invented BioBike, a web-based biological knowledge platform enabling biologists to develop, run, and share complex analyses of genomic information. Dr. Shrager holds degrees in computer science and cognitive neuroscience from The University of Pennsylvania and CMU, and publishes extensively in scientific computing, AI, biology, genomics, and the cognitive sciences.

Raphael Lehrer directs CollabRx ONE, our personalized oncology research service. Previously, Dr. Lehrer was the Executive Director of Strategic Alliances for Gene Logic's Drug Repositioning and Selection Business where he negotiated alliances with pharmaceutical companies to discover new therapeutic uses for their compounds that have failed in late-stage clinical trials. In earlier positions at Gene Logic, he played a key role in formulating strategy for the company; evaluating, acquiring, and integrating the preclinical CRO business; and in adding service-based offerings to Gene Logic's toxicogenomics business. Prior to joining Gene Logic, Dr. Lehrer worked at The Boston Consulting Group, where he supported top-ten pharmaceutical clients on a variety of R&D and commercial issues, including formulating licensing strategies, clinical development process design, regulatory processes, post-merger integration, and outsourcing strategies. Additionally, Dr. Lehrer was a key contributor to BCG's positioning paper on the impact of genomics on pharmaceutical R&D. Dr. Lehrer holds a B.S. degree in Physics from Yale University and a Ph.D. degree in Physics from Harvard University, where he was awarded the Maurice Goldhaber Prize for best theoretical physics student.

Prior to joining CollabRx, Dr. Coopersmith was Director of In Silico Biology at Ore Pharmaceuticals Before that, he led the bioinformatics group at UCB Pharma, where he oversaw genomics-based microarray discovery projects in the CNS therapeutic area. Dr. Coopersmith has been responsible for bioinformatics functions at several leading biotechnology companies, including Millennium Pharmaceuticals and Incyte Genomics. He has also held research and teaching positions at Mclean Hospital/Harvard Medical School, Massachusetts General Hospital, Boston College, and SUNY at Binghamton, NY. Dr. Coopersmith received a Ph.D. in Biological Sciences from the University of California, Irvine. He has authored numerous publications and patents.

Dr. Vidwans brings extensive industry and academic experience in R&D strategy, early stage drug discovery, business development, and strategy and program management. She has consulted with a wide range of pharmaceutical companies, including Pfizer, GlaxoSmithKline, Roche Biosciences, Wyeth, Schering-Plough, on business strategy development, implementation and change management. She worked with McKinsey & Company where she was a key contributor to their Healthcare practice. She has also consulted with non-profits including the Institute for OneWorld Health and several startups in the drug discovery space. Dr. Vidwans was adjudged amongst the top 100 young investigators under 35 for her work on Tuberculosis drug discovery. She holds a Ph.D. in Genetics and Developmental Biology from the University of California, San Francisco, and an S.B. in Biology from the Massachusetts Institute of Technology.